08:00 , Dec 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Neurology INDICATION: Neurology A mouse study suggests the mitochondrial-targeting antioxidant MitoQ could help treat Angelman syndrome. Hippocampal levels of mitochondrial superoxide were higher in a mouse model of Angelman syndrome than in normal mice. In...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Not applicable Mouse studies suggest the mitochondria-targeted coenzyme Q10 analog mitoquinone could help treat obesity. In mice fed a high-fat diet, mitoquinone decreased...
07:00 , May 3, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Mitochondria; glycolysis Studies in cell culture suggest combining mitochondrial antioxidants and glycolysis inhibitors could help treat breast cancer. In cultured breast cancer cell...
08:00 , Nov 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Procaspase-3; procaspase-6; caspase-3 (CASP3; CPP32); caspase-6 (CASP6; MCH2) Studies in cell culture suggest that small molecule activators of procaspases could help treat cancer. High...
08:00 , Nov 20, 2008 |  BC Innovations  |  Cover Story

Figure 1. Iron in Parkinson's disease

Figure 1. Iron in Parkinson's disease Figure 1. Iron in Parkinson's disease. Targeting iron or iron-related reactions in the neuron could lead to potential treatments in Parkinson's disease (PD). Salazar et al . suggest that...
08:00 , Nov 20, 2008 |  BC Innovations  |  Cover Story

Testing Parkinson's metal

The search for disease-modifying therapeutics in Parkinson's disease has been stymied by a lack of consensus about whether the disease is caused by free radical formation, protein aggregation or mitochondrial dysfunction. Now, a pair of...
07:00 , Apr 28, 2008 |  BC Week In Review  |  Clinical News

MitoQ: Phase II data

In a double-blind, New Zealand Phase II trial in 30 HCV patients, MitoQ met the primary endpoint of significantly reduced ALT levels vs. placebo. Compared with placebo, patients receiving 40 or 80 mg/day of MitoQ...
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

MitoQ: Phase II started

The company began a placebo-controlled, New Zealand Phase II trial in 36 patients who have been unresponsive to, or unsuitable for treatment with pegylated interferon plus ribavirin. Antipodean Pharmaceuticals Inc. , San Francisco, Calif.  ...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Clinical News

MitoQ: Completed Phase II enrollment

Antipodean completed enrollment of 128 patients in a double-blind, placebo-controlled, New Zealand and Australian Phase II trial. The trial is evaluating 40 and 80 mg doses of once-daily oral MitoQ. Antipodean Pharmaceuticals Inc. , San...
07:00 , May 29, 2006 |  BC Week In Review  |  Clinical News

MitoQ: Phase II started

Antipodean began a double-blind, placebo-controlled, New Zealand and Australian Phase II trial in 120 treatment-naïve patients to receive 40 or 80 mg/day MitoQ. Antipodean Pharmaceuticals Inc. , San Francisco, Calif.   Product: MitoQ   Business:...